Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.

Assembly Bill A5921 exempts drug manufacturers and wholesale distributors from needing a pharmacist license when distributing dialysate drugs or devices for home dialysis to patients with kidney failure. It applies only under specific conditions: drugs must be FDA-approved, delivered in original sealed packaging with a physician's order, directly to patients, their designees, or healthcare providers, and manufacturers must contract with a consultant pharmacist for weekly quality checks. This change specifically affects companies distributing dialysis supplies for home use, removing a licensing barrier for these transactions while maintaining pharmacist oversight. The bill does not alter existing requirements for pharmacists or other drug distribution.